Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
More News related to CPRX
- Catalyst Receives Guidance from Nasdaq Regarding Minimum Bid Price Requirement
- Catalyst Pharma. (CPRX) Posts Q3 Loss of $0.09, Tops by 2c
- Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
- Catalyst Pharma (CPRX) Receives $1.2M Grant from U.S. DoD for Study of Vigabatrin
- U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of Defense (DOD) to conduct an animal study of the use of vigabatrin in combination with opiates to effectively manage pain while reducing the potential for opiate addiction. Opioid abuse is one of the many substance addiction indications covered under Catalyst's exclusive license of Brookhaven National Laboratory's vigabatrin patent portfolio. With this in mind, Catalyst has agreed to provide CPP-109, Catalyst's version of vigabatrin, to facilitate the study.
The research team is led by Wynne K. Schiffer, Ph.D. and Stephen L. Dewey, Ph.D. of The Feinstein Institute for Medical Research and Jonathan D. Brodie, M.D., Ph.D. from the Department of Psychiatry at New York University's School of Medicine. Dr.'s Dewey and Brodie are the co-inventors on the vigabatrin-related patents that Catalyst has licensed from Brookhaven and are members of Catalyst's Scientific Advisory Board. Drs. Schiffer and Dewey have recently moved from Brookhaven to The Feinstein Institute.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
